U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06860386) titled 'Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC' on March 04.
Brief Summary: This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Study Start Date: Feb. 25
Study Type: INTERVENTIONAL
Condition:
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Intervention:
DRUG: Pembrolizumab
200 mg every 3 weeks IV infusion (Q3W + or -3 days)
DRUG: Axitinib
5 mg twice daily (BID) by mouth
Recruitment Status: RECRUITING
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Published by HT ...